Reata announces data demonstrating potential of omaveloxolone in Friedreich's Ataxia
Reata Pharmaceuticals announced new preclinical data demonstrating that omaveloxolone potently activates the Keap1/Nrf2 pathway, significantly reduces production of reactive oxygen species, and improves mitochondrial function in two different models of severe neurological diseases. April 24, 2018